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body mass index (BMI) ≥ 30. 62.2% of respondents reported taking steps to lose weight. 
These respondents were more likely to be female, of higher socioeconomic status, 
and more knowledgeable about their health (all p< .05). Among respondents who 
were trying to lose weight, only 27.5% had consulted a specialist. The primary reason 
for weight loss was to improve health (60.8%). Despite these intentions, success was 
limited. Only 34.3% reported having lost weight in the past 6 months (43.3% reported 
gaining weight) and the mean weight change was 0.5 kilograms (SD = 7.3). The most 
common treatments used for weight loss included exercise and dieting; 27.6% and 
17.1% of respondents have used an over the counter (OTC)/herbal product and a 
prescription medication, respectively. Discontinuation rates were high with these 
treatments, as only between 28.0% and 48.8% of respondents who ever used OTC/
herbal products and prescription medications, were currently using those methods. 
Mean monthly out-of-pocket costs for OTC and prescription medications (combined) 
did not vary by socioeconomic status. ConClusions: The majority of respondents 
were taking steps to lose weight, employing a variety of strategies. Unfortunately, suc-
cess of these strategies was limited. Additional weight loss treatments and increased 
obesity management advice may help improve weight loss success.
PSY13
The Burden of oBeSiTY in Mexico: Prevalence, coMorBidiTieS, and 
aSSociaTionS WiTh QualiTY of life, reSource uTilizaTion and 
ProducTiviTY
DiBonaventura MD1, Le Lay A2, Fournier J2, Kull K2, Olmos HC3, Mille I3, Bjørke B2, Bakker 
E3, Ehrenreich A1
1Kantar Health, New York, NY, USA, 2Novo Nordisk A/S, Bagsværd, Denmark, 3Novo Nordisk A/S, 
Mexico City, Mexico
objeCtives: This study investigated the effect of body mass index (BMI) and related 
comorbidities on quality of life, work productivity, activity impairment, healthcare 
resource utilization, and associated costs in Mexico. Methods: Data were collected 
using a cross-sectional survey of adults in Mexico (N= 2,511) identified from a combi-
nation of Internet panels and offline recruitment. Recruitment was made to ensure 
the demographic composition of the sample mimicked the total adult population. 
The analysis focused on respondents with normal weight (BMI≥ 18.5 & < 25 kg/m2), 
overweight (BMI≥ 25 & < 30 kg/m2), obesity class I (BMI≥ 30 & < 35 kg/m2), class II 
(BMI≥ 35 & < 40 kg/m2), or class III (BMI≥ 40 kg/m2). Demographics, comorbidities (e.g., 
hypertension, dysglycaemia), health outcomes such as quality of life (EQ-5D), work 
productivity and activity impairment (WPAI questionnaire), healthcare resource utili-
zation, and indirect costs were assessed. Generalized linear models were used to test 
the association between BMI levels and health outcomes, controlling for covariates 
(e.g., age, sex, comorbidities). Results: The sample was 50.6% male with a mean age 
of 40.7 years (SD= 14.5); 38.3% were overweight and 24.4% reported a BMI≥ 30. 75.2% of 
individuals with BMI ≥ 35 had dysglycaemia (29.9% type 2 diabetes mellitus (T2DM) 
and 45.3% pre-diabetes). Increasing BMI was associated with significant impairment 
in quality of life (health utilities ranging from 0.84 for normal weight, down to 0.76 for 
people with BMI≥ 35). Increasing BMI was also associated with greater overall work 
impairment (from 18.8% up to 25.8%), activity impairment (from 15.8% up to 24.8%), 
and indirect costs (from 35122 MXN up to 48090 MXNs). A similar pattern of results 
was found in the T2DM, pre-diabetes, and hypertension subgroups. ConClusions: 
Results suggest a significant effect of increasing BMI and comorbidities on quality of 
life and work productivity. Improvement in the management of the obesity epidemic 
could have significant benefits to the patient and society.
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objeCtives: Leptospirosis is a zoonotic infection endemic in Malaysia. This study 
was conducted to describe the clinical features and laboratory findings of leptospi-
rosis in a tertiary care hospital of Malaysia Methods: This is a retrospective study 
including 79 consecutive patients with leptospirosis admitted to tertiary hospitals in 
Kelantan, Malaysia from 2009 to 2011. All patients had clinical and epidemiological 
data suggestive of leptospirosis, and positive laboratorial test for leptospirosis were 
included in this study. Hospital database were used to extract all the required infor-
mation Results: A total of 79 patients (mean age: 36.8 ± 12.4 years) were included 
among them 68.5% were male. Duration of symptoms onset to hospital admission 
was 6.7 ± 2.6 days. The most common clinical findings among patients at admis-
sion were arthralgia (90.1%), fever (86.5%), jaundice (98.3%) and myalgia (87.2%). 
Other common clinical manifestations were abdominal discomfort (78.8%), leth-
argy (33.2%) headache (68.2%), vomiting (82.4%), bleeding (39.9%) and dehydration 
(72.6%). Among leptospiral intricacies hepatic failure (66.4%), acute kidney injury 
(69.5%), acute respiratory distress syndrome (2.2%), pulmonary failure (33.1%), visual 
impairments (3.6%), rhabdomyolosis (12.2%) of the patients. Thrombocytopenia and 
hematuria were observed in 58.3% and 34.2% of total cases respectively. Mean days 
of hospitalization were 6.2 ± 2.3 days. Mortality was observed in 11 cases (14%). All 
the fatal cases have more than one organ failure ConClusions: Leptospirosis is 
zoonotic fatal and highly morbid disease. Several clinical complications associ-
ated with leptospirosis lead to high mortality and morbidity. Early diagnosis and 
adequate management can reduce morbidity and mortality associated with lep-
tospirosis
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at least € 457K for the Portuguese NHS. ConClusions: Dexmedetomidine reduces 
the duration of mechanical ventilation and is a cost-saving alternative to propofol 
at the ICU setting.
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objeCtives: Absolute iron deficiency related to depletion of iron stores or func-
tional iron deficiency are the main causes of anemia, which can trigger hospitali-
zation and even mortality. International guidelines recommend intravenous (IV) 
iron therapy for several chronic conditions. Intravenous iron is more effective, 
better tolerated, and improves the quality of life to a greater extent than oral 
iron supplements. Ferric carboxymaltose (FCM) and iron sucrose (IS) are IV iron 
drugs available in the Brazilian market. Considering this scenario the purpose 
of the study is to perform a cost minimization analysis of FCM versus IS under 
the supplementary health setting. Methods: Due to no non-inferiority study 
design comparing both IV therapies, a cost-minimization analysis was conducted. 
Treatment expenditures were accounted considering drugs acquisition costs and 
infusion related costs. Drugs ex-factory prices were obtained in official price list. 
Infusion fees were accessed through research conducted in 36 private hospitals 
distributed in service categories. In each institution the information collected 
was: place of infusion, materials, medical honoraries, room fee and price lists. An 
average patient was assumed (70kg; Hb≤ 10,5g/dL) which would receive a total iron 
dose of 1,000mg in both regimens. According to label, FCM can be administrated in 
a single dose whereas IS requires 5 infusions of 200 mg iron given up twice weekly. 
Deterministic one-way sensitivity analysis was performed. Costs were reported in 
Brazilian currency. Results: Treatment cost for FCM (BRL927.69) was lower than 
IS (BRL 1,184.97), due to more infusions required for treatment with IS. The number 
and cost of the infusions were the most influential parameters in the analysis, 
and even with variations of ± 20% in all parameters, treatment results with FCM 
remained favorable. ConClusions: FCM represents a cost-saving option com-
pared with other IV therapy alternative used in the management of anaemia in 
the Brazilian Supplementary Health System.
PSY10
coST-MiniMizaTion analYSeS of adaliMuMaB coMPared WiTh 
SelecTive iMMunoSuPPreSSive cYTokineS BlockerS and inhiBiTorS 
of TuMor necroSiS facTor alPha indicaTed for The TreaTMenT of 
rheuMaToid arThriTiS, PSoriaSiS and crohn’S diSeaSe in The PrivaTe 
MarkeT in Mexico
Pichardo-Piña CA, Sánchez-Casillas JL, Pozos-Espíndola JC
AbbVie, Distrito Federal México, Mexico
objeCtives: To compare the cost of treating rheumatoid arthritis, psoriasis and 
Crohn’s disease with adalimumab compared with selective immunosuppressive 
cytokines blockers and inhibitors of tumor necrosis factor-alpha. Methods: We 
conducted a through systemic review of the literature and compared data from 
adalimumab with etanercept, abatacept, infliximab, tocilizumab, certolizumab 
pegol and golimumab in treating rheumatoid arthritis, with etanercept, inflixi-
mab, and ustekinumab in the treatment of plaque psoriasis, and with infliximab 
and certolizumab pegol in the treatment of Crohn’s disease. A cost minimization 
analysis was then considered appropriate under the perspective of a private health 
care provider in Mexico and a time horizon of five years. The costs of medication 
and application (2014) were considered. It has been assumed that patients have 
a weight of 70 kg based on the National Health and Nutrition Survey 2012 and a 
discount rate of 5% was applied. Results: Adalimumab proved to be less expen-
sive in the base case against considered alternatives. The total discounted cost of 
using adalimumab for 5 years for rheumatoid arthritis was $ 1,030,807.61 (followed 
by abatacept -$1,032,233.83- and certolizumab -$1,093,401.30-); in the case of pso-
riasis was $ 1,047,883.48 (followed by ustekinumab -$1,210,738.82- and etanercept 
-$1,237,387.15-); for Crohn’s disease was $ 1,072,947.28 (followed by infliximab 
-$1,353,574.18- and certolizumab -$2,091,555.72-). ConClusions: Treatment with 
adalimumab incurs lower costs compared with etanercept, abatacept, infliximab, 
tocilizumab, certolizumab pegol and golimumab in treating rheumatoid arthritis; 
etanercept, infliximab, and ustekinumab in the treatment of psoriasis and certoli-
zumab pegol and infliximab in treating Crohn’s disease. Further budget impact 
and probabilistic sensitivity analyses could provide additional information about 
these alternatives.
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objeCtives: This study investigated the treatment patterns of those who are attempt-
ing to lose weight in Mexico. Methods: Data were collected using a cross-sectional 
survey of adults in Mexico (N= 2,511) identified from a combination of internet panels 
and offline recruitment. Recruitment was made to ensure the demographic composi-
tion of the sample mimicked that of the total adult population. Respondents provided 
data on their demographics, health history, weight loss intentions and treatments 
used, weight change, and out-of-pocket costs. Results: The sample was 50.6% male 
with a mean age of 40.7 years (SD= 14.5); 38.3% were overweight and 24.4% reported a 
